Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

K Hiraoka, M Miyamoto, Y Cho, M Suzuoki, T Oshikiri, Y Nakakubo, T Itoh, T Ohbuchi, S Kondo, H Katoh, K Hiraoka, M Miyamoto, Y Cho, M Suzuoki, T Oshikiri, Y Nakakubo, T Itoh, T Ohbuchi, S Kondo, H Katoh

Abstract

The purpose of this study was to clarify the relationship between the number of tumour-infiltrating T lymphocytes and the clinicopathological features and clinical outcome in patients with non-small-cell lung cancer (NSCLC). Tissue specimens from 109 patients who underwent surgical resection for NSCLC were immunohistochemically analysed for CD4 and CD8 expression. Patients were classified into two groups according to whether their tumours exhibited a 'high' or 'low' level of CD8(+) or CD4(+) lymphocyte infiltration. Although the level of infiltration by CD8(+) T cells alone had no prognostic significance, the survival rate for patients with both 'high' CD8(+) and 'high' CD4(+) T-cell infiltration was significantly higher than that for the other groups (log-rank test, P=0.006). Multivariate analysis indicated that concomitant high CD8(+) and high CD4(+) T-cell infiltration was an independent favourable prognostic factor (P=0.0092). In conclusion, the presence of high levels of both CD8(+) T cells and CD4(+) T cells is a significant indicator of a better prognosis for patients with NSCLC, and cooperation between these cell populations may allow a significantly more potent antitumour response than either population alone.

Figures

Figure 1
Figure 1
Representative immunohistochemical staining of NSCLC tumour sections. (A) Adenocarcinoma (anti-CD8 antibody; original magnification, × 200). (B) Adenocarcinoma (anti-CD4 antibody, × 200). (C) Squamous cell carcinoma (anti-CD8 antibody, × 200). (D) Squamous cell carcinoma (anti-CD8 antibody, × 400). Arrows indicate CD8-positive stained lymphocytes.
Figure 2
Figure 2
The correlation between the number of CD8+ T cells in cancer stroma and within cancer cell nests in patients with NSCLC.
Figure 3
Figure 3
Kaplan–Meier analysis of overall survival according to (A) the level of infiltration by CD8+ T cells in cancer stroma, (B) the level of infiltration by CD4+ T cells in cancer stroma and (C) the simultaneous presence of high levels of infiltrating CD8+ T cells and CD4+ T cells in cancer stroma in patients with NSCLC. For details about the method of classification, see Materials and Methods. aHigh-CD8+/high-CD4+ group (n=26) vs others (n=83).

References

    1. Cheng TY, Wu JT, Lin RH (1998) Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells. Int Immunol 10: 1397–1406
    1. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555–1559
    1. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991a) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815–3822
    1. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A (1991b) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444–3451
    1. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: e26–31
    1. Goodenow RS, Vogel JM, Linsk RL (1985) Histocompatibility antigens on murine tumors. Science 230: 777–783
    1. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281–355
    1. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363–1366
    1. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188: 2357–2368
    1. Hunt JD, Robert EG, Zieske AW, Bautista AP, Bukara M, Lei D, Shellito JE, Nelson S, Kolls JK, Skrepnik N (2000) Orthotopic human lung carcinoma xenografts in BALB/c mice immunosuppressed with anti-CD4 monoclonal antibodies and chronic alcohol consumption. Cancer 88: 468–479
    1. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327: 1434–1441
    1. Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM (2001) The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61: 1500–1507
    1. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 52: 1386–1392
    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A, Feuer E, Thun M (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30
    1. Melero I, Bach N, Chen L (1997) Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci 60: 2035–2041
    1. Mori M, Ohtani H, Naito Y, Sagawa M, Sato M, Fujimura S, Nagura H (2000) Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 191: 113–118
    1. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96: 8633–8638
    1. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491–3494
    1. Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H (2003) Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 89: 1736–1742
    1. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132–5136
    1. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909
    1. Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S, Katoh H (2003) Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 84: 224–228
    1. Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12: 677–686
    1. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177: 265–272
    1. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380–384
    1. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter CS, Bock S, Schwartzentruber DJ, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676–1680
    1. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321–327
    1. Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932–3936
    1. Sobin LH, Wittekind CH (1997) UICC TNM Classification of Malignant Tumors. New York: John Wiley & Sons Inc.
    1. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells – a mechanism of immune evasion? Nat Med 2: 1361–1366
    1. Takanami I, Takeuchi K, Giga M (2001) The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 121: 1058–1063
    1. Takeo S, Yasumoto K, Nagashima A, Nakahashi H, Sugimachi K, Nomoto K (1986) Role of tumor-associated macrophages in lung cancer. Cancer Res 46: 3179–3182
    1. Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C (1999) Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer 82: 377–384
    1. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M (2003) CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94: 1003–1009
    1. Wang RF (2001) The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 22: 269–276
    1. Wang RF, Rosenberg SA (1999) Human tumor antigens for cancer vaccine development. Immunol Rev 170: 85–100
    1. Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, Nomoto K (1992) Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52: 775–781
    1. Zeng G (2001) MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J Immunother 24: 195–204

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever